Browse by Series:

Real-World Management of Patients with BRAF-V600E mCRC

Insights From: Scott Kopetz, MD, PhD, FACP, The University of Texas MD Anderson Cancer Center; Ryan Corcoran, MD, PhD, Massachusetts General Hospital Cancer Center
Published: Thursday, Jan 31, 2019



Scott Kopetz, MD, PhD, FACP, provides advice on the management of patients with BRAFV600E-mutant metastatic colorectal cancer with the triplet regimen of encorafenib, binimetinib, and cetuximab, a regimen studied in the BEACON and ANCHOR trials.
SELECTED
LANGUAGE
Slider Left
Slider Right


Scott Kopetz, MD, PhD, FACP, provides advice on the management of patients with BRAFV600E-mutant metastatic colorectal cancer with the triplet regimen of encorafenib, binimetinib, and cetuximab, a regimen studied in the BEACON and ANCHOR trials.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x